TrialNature medicine2023

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Alexander M Lesokhin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.